Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the safety and efficacy of KBA1412, a patient derived,
fully human, monoclonal antibody targeting CD9, in patients with advanced solid malignant
tumors